Tonix Pharma Reports Q3 2025 Financials & Highlights
Tonix Pharmaceuticals will launch Tonmya, a sublingual 2.8 mg formulation of cyclobenzaprine for fibromyalgia in adults, before the end...
Tonix Pharmaceuticals will launch Tonmya, a sublingual 2.8 mg formulation of cyclobenzaprine for fibromyalgia in adults, before the end...
Orchestra BioMed has secured $147.6 million in gross proceeds through a mix of strategic transactions and public and private...
Beyond Air reported a 128% year-over-year revenue increase to $1.8 million for its fiscal second quarter. It secured up...
Mereo BioPharma reported third-quarter 2025 results with cash of $48.7 million and a stated runway into 2027, while confirming...
FibroGen has closed the sale of FibroGen China to AstraZeneca for approximately $220 million and used the proceeds to...
Harrow reported third-quarter 2025 revenue of $71.6 million, up 45% year over year, returning to GAAP profitability with $1.0...
Assembly Biosciences reported positive interim Phase 1b results for ABI-5366 in recurrent genital herpes, showing reductions in HSV-2 shedding,...
Insight Molecular Diagnostics plans to submit its first kitted transplant rejection assay, GraftAssureDx, to the FDA by year-end, holding...
Jasper Therapeutics reported third-quarter 2025 results and a corporate update centered on briquilimab, its anti-KIT antibody in chronic urticaria...
Kamada reported third-quarter 2025 revenues of $47.0 million, up 13% year over year, with adjusted EBITDA up 34% to...